Exelixis shares fell 3% after the US Food and Drug Administration extended the review period for the company's anti-cancer drugs.

Zhitongcaijing · 2d ago
Exelixis shares fell 3% after the US Food and Drug Administration extended the review period for the company's anti-cancer drugs.